top of page
Executive Spotlights

Normunity Announces $65 Million Series a Financing to Expand Frontier of Precision Immuno-Oncology

Boston & West Haven, CT, October 25, 2022 (Business Wire) -- Normunity, Inc., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced its launch and Series A financing of $65 million. The Series A was led by Canaan Ventures and included participation by Sanofi Ventures, Taiho Ventures and Osage University Partners. Normunity’s new class of agents, called immune normalizers, target previously undiscovered mechanisms of immune disruption in cancer. The company’s pipeline is drawn from the ongoing and interactive academic-biotech research taking place at Yale School of Medicine, leveraging proprietary discovery platforms from the lab of Dr. Lieping Chen, an immuno-oncology luminary who identified PD-L1 (B7-H1) among other seminal contributions to the field.

Read full article here.

Recent Posts

See All


Life Science Headlines
bottom of page